Issue 10, 2023

Antitumour imidazotetrazines: past, present… and future?

Abstract

It is 40 years since the publication of the patent that announced the imidazotetrazines temozolomide and mitozolomide to the world and 30 since the discovery that they function as prodrugs of alkyldiazonium reactive intermediates. Temozolomide combined with radiation is established as the first-line treatment for glioma but despite the attentions of the inventors and others, further examples of this intriguing ring system have yet to enter the clinic.

Graphical abstract: Antitumour imidazotetrazines: past, present… and future?

Transparent peer review

To support increased transparency, we offer authors the option to publish the peer review history alongside their article.

View this article’s peer review history

Article information

Article type
Review Article
Submitted
25 May 2023
Accepted
18 Aug 2023
First published
29 Aug 2023
This article is Open Access
Creative Commons BY-NC license

RSC Chem. Biol., 2023,4, 736-741

Antitumour imidazotetrazines: past, present… and future?

M. F. G. Stevens and R. T. Wheelhouse, RSC Chem. Biol., 2023, 4, 736 DOI: 10.1039/D3CB00076A

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements